Abstract. Loss of large tumor suppressor kinase 1 (LATS1)Y has been implicated in numerous types of human cancer. However, its involvement in human cervical cancer remains to be elucidated. The present study aimed to investigate the clinical significance and biological characteristics of LATS1 in human cervical cancer. The present study investigated the protein expression levels of LATS1 in tissues from 80 cases of cervical cancer using immunohistochemistry and demonstrated that LATS1 was downregulated in 45% (36/80) of cervical cancers. Transfection of LATS1 was performed in the SiHa cell line and LATS1 siRNA knockdown was performed in the Caski cell line. MTT assay and Matrigel invasion assay indicated that LATS1 overexpression inhibited cell proliferation and invasion. LATS1 overexpression upregulated p27 expression, and downregulated the expression of cyclin E and matrix metalloproteinase 9. In addition, LATS1 overexpression stimulated yes-associated protein 1 (YAP) phosphorylation. Depletion of LATS1 in Caski cells resulted in the opposite effects. The current study demonstrated that LATS1 was downregulated in cervical cancer and may suppress cell growth and invasion through regulating the expression of cyclin E, p27, MMP9 and YAP.
Introduction
Cervical cancer is the third most common malignancy in women worldwide, with a global incidence of 500,000 and a mortality of 250,000 in 2014 (1) . For the earliest stage of cervical cancer, >90% of women survive at least 5 years after diagnosis. However, advanced cervical cancer with invasion or metastasis is associated with a poor prognosis, <20% of stage IV patients survive for ≥5 years (2) . Furthermore, despite advances of conventional therapies such as surgical treatment, radiotherapy and chemotherapy, malignant cervical cancers still have high mortality rate, and the mechanism underlying its aggressiveness remains poorly understood. Thus, the identification of novel molecular markers, which is helpful for the development of novel diagnostic and therapeutic strategies, remains an important focus in the current management of this malignancy.
Mammalian Large tumor suppressor kinase 1 (LATS1) and LATS2, the major kinase components of the Hippo pathway, are important in the control of tumor development (3, 4) and the cell cycle, via various mechanisms and signaling pathways (5, 6) . It was previously reported that LATS1 protein was downregulated in various types of cancer, including breast carcinoma (7) , colorectal carcinoma (8) , gastric cancer (9) , non-small cell lung cancer (10) and ovarian serous carcinoma and clear cell carcinoma (11) . These results indicated that LATS1 may be an important tumor suppressor in types of human cancer. However, whether LATS1 is a tumor suppressor in cervical cancer remains controversial.
The present study examined LATS1 protein expression in 80 cases of cervical carcinoma and analyzed the association between LATS1 expression and clinicopathological factors. Additionally, gain of function and loss of function experiments were performed to investigate the biological roles of LATS1 in cervical cancer. LATS1 expression was upregulated in SiHa cells and depleted in Caski cells, and the effects on cell proliferation and invasion were then examined. In addition, the molecular signaling pathways underlying these biological effects of LATS1 were investigated. Two independent blinded investigators examined all tumor slides randomly. As in previous studies (13, 14) , immunostaining of LATS1 was scored on a semi-quantitative scale by evaluating the intensity and percentage of tumor cells stained. Cytoplasmic immunostaining was regarded as positive. The intensity of LATS1 staining was scored as follows: 0, weak/negative; 1, moderate; or 2 (strong). Staining percentage, the percentage of tumor cells stained, was scored as follows: 1, 1-25%; 2, 26-50%; 3, 51-75%; or 4, 76-100%. Total score was obtained by multiplying the staining and percentage scores. Specimens with a total score of 5-8 were considered to be positive for LATS1 expression. Specimens with a total score of 0-4 were considered to have low LATS1 expression.
Materials and methods

Patients and specimens.
Cell culture and transfection. Caski, HeLa and SiHa cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). SiHa and HeLa cells were cultured in minimum essential medium (MEM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and Caski cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) at 37˚C for 2 days. Cells were cultured on sterilized culture plates and were passaged every two days with trypsin.
The plasmid of pCMV6-LATS1 was purchased from (OriGene Technologies, Inc. (Rockville, MD, USA) Plasmid was transfected into cells using Lipofectamine ® 3000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) at 37˚C for 48 h. pCMV6 empty vector was used as a negative control. For transient knockdown experiments, oligonucleotide pools of small interfering RNA (siRNA) targeting LATS1 and non-targeting siRNA (cat. no. M-004632-00-0005) were purchased from Dharmacon (Lafayette, CO, USA) and transfected using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) at 37˚C for 48 h, according to the manufacturersprotocols.
Western blot analysis. Proteins were extracted and quantified using the Bradford method, and 20 µg protein was separated by SDS-PAGE (5% stacking gel and 10% separating gel). Proteins were transferred to polyvinylidene fluoride membranes and 5% BSA solution (w/v) was used to reduce non-specific antibody binding at room temperature for 1 h. Proteins were incubated overnight at 4˚C with antibodies against LATS1 MTT assay. Cells were plated in 96-well plates in MEM containing 10% fetal bovine serum at approximately 1,000-1500 cells per well. For the measurement of cell viability, 20 µl MTT solution was added to each well and incubated at 37˚C for 4 h. Subsequently, the remaining MTT formazan was dissolved in 150 µl dimethyl sulfoxide. The plate was measured at a wavelength of 490 nm using a plate reader.
Cell invasion analysis. Cell invasion was examined using
Transwell assay with 24-well Transwell chambers. Briefly, Transwell chamber inserts were coated using 20-25 µl Matrigel from BD Biosciences (Franklin Lakes, NJ, USA) with a dilution of 1:5. ~48 h after cell transfection, ~1x10 5 cells were re-suspended in 100 µl of serum-free MEM and were added to the upper chamber. MEM with 10-15% fetal bovine serum was added to the lower chamber. After incubation at 37˚C for 16-20 h, cells on the upper side of membranes were removed using a cotton swab and the cells that had invaded through the filter were washed with phosphate-buffered saline and visualized with hematoxylin at room temperature for 5 min. The number of invaded cells was counted in 5 randomly selected high power fields using a light microscope. This experiment was performed in triplicate.
Statistical analysis. SPSS version 11.5 for Windows (SPSS, Inc., Chicago, IL, USA) was used for all statistical analyses. Data was presented as mean ± standard deviation. χ 2 test was used to examine potential associations between LATS1 expression and clinicopathological factors and a paired Student-s t-test was used to compare other data generated from LATS1-transfected or knockdown cells. P<0.05 was considered to indicate a statistically significant difference.
Results
Clinical significance of LATS1 in human cervical cancer. LATS1 expression was located in the cytoplasm in normal cervical tissues (Fig. 1A) . Of the 80 cervical cancer tissues, 46 of them (45%) exhibited decreased LATS1 staining, although others were positive for LATS1 expression (Fig. 1B-D) .
The potential association of low LATS1 expression with clinicopathological characteristics was analyzed. The results demonstrated that low LATS1 immunostaining in cervical cancer was significantly associated with primary tumor, node, metastasis (TNM) stage (stages II+III vs. stage I, P=0.0102) and primary tumor (T) stage (TII+III vs. TI, P=0.0217). No significant association was identified between low LATS1 expression and other parameters, including age, histological type and differentiation (Table I) .
LATS1 suppresses proliferation and invasion of cervical cancer cells. LATS1 was examined by western blot analysis in cervical cancer cell lines (Fig. 2A) . The present study demonstrated that SiHa cells had low LATS1 protein expression and Caski cells had relatively high LATS1 protein expression. To determine its biological roles in cervical cancer cell lines, plasmid transfection was performed in SiHa cells and siRNA knockdown was performed in Caski cells. As presented in 
LATS1 regulates the expression of cyclin E, p27, MMP9 and YAP in cervical cancer cells.
In order to investigate the molecular mechanism underlying LATS1-induced cell growth and invasion, the present study examined the expression of growth and invasion-associated proteins. The results demonstrated that the cyclin E expression was notably decreased following LATS1 Protein expression of cell cycle inhibitor p27 was increased compared to control following LATS1 transfection in SiHa cells and decreased compared to the control following LATS1 knockdown in Caski cells. (Fig. 4A) . The present study also examined invasion-associated protein MMP9, and demonstrated that MMP9 was downregulated in LATS1-transfected SiHa cells and upregulated in LATS1-knockdown Caski cells, compared to respective controls (Fig. 4A) . LATS1 is the upstream inhibitor of Hippo signaling. Activation of the Hippo signaling pathway inhibits the expression and function of YAP oncoprotein and suppresses cancer growth and invasion. The current study examined YAP expression, and its downstream factor CTGF, in LATS1 overexpressing and knockdown cervical cancer cells. As presented in Fig. 4B , in LATS1-transfected SiHa cells, CTGF and YAP levels were decreased, compared to the control SiHa cells. In LATS1 knockdown Caski cells, their expression (YAP and CTGF) was upregulated compared with control Caski cells. Changes in the levels of YAP phosphorylation were also examined. Western blot analysis demonstrated that LATS1 increased the phosphorylation of YAP.
Discussion
LATS1 is the mammalian homolog of Drosophila LATS, originally identified as a cell proliferation inhibitor (15) . It is a serine/threonine kinase that localizes to the mitotic apparatus. LATS1 may form a complex with cyclin-dependent kinase 1 in early mitosis, decreasing H1 histone kinase activity, which indicates its role as a cell cycle inhibitor (16) . LATS1-knockout mice developed sarcomas and ovarian tumors, indicating that it may also function as a tumor suppressor (3). The expression and biological roles of LATS1 have been implicated in a number of human malignancies, including gastric cancer, breast cancer, glioma, renal cell carcinoma and ovarian cancer (9, 11, (17) (18) (19) . However, to the best of our knowledge, the involvement of LATS1 in human cervical carcinoma has not been reported. The present study examined LATS1 protein expression in 80 cases of cervical cancer and demonstrated that LATS1 was downregulated in 45% of tissue specimens. Statistical analysis demonstrated that LATS1 downregulation was positively associated with advanced TNM stage and tumor status, indicating that loss of LATS1 is associated with cervical cancer progression. The results of the current study are consistent with previous studies (20) (21) (22) , indicating that LATS1 may be a potential tumor suppressor in human cervical cancer.
To identify its biological roles in cervical cancer cells, the present study transfected SiHa cells with a LATS1 plasmid and Caski cells were transfected with LATS1 siRNA. Subsequently, the effects on cell proliferation and invasion were examined. Consistent with the immunohistochemical results of the present study, LATS1 transfection significantly inhibited cell growth and invasiveness of SiHa cells, while LATS1 siRNA had the opposite effect in Caski cells. The current study further investigated progression (23, 24) . Cycle E overexpression is important during cervical cancer proliferation (25) , and p27 downregulation has been previously identified in cervical cancer tissues where it may cause cell cycle arrest in cervical cancer cells (26, 27) . In addition, the present study demonstrated that invasion-associated protein MMP9 was negatively regulated by LATS1 expression. MMP9 is considered to be associated with cervical cancer invasion (28) (29) (30) . Thus LATS1 may regulate cervical cancer growth and invasion through modulation of cell cycle proteins and MMP9. As LATS1 is the upstream positive regulator of Hippo pathway, the current study investigated changes in the expression levels of downstream proteins, including YAP and CTGF. The results demonstrated that LATS1 overexpression inhibited CTGF and YAP expression, and increased YAP phosphorylation in SiHa cells compared with control SiHa cells. YAP is a positive regulator of growth and invasion in various types of human cancers, including cervical cancer (31) . CTGF is the target of YAP and functions as a growth promoter. CTGF has been reported to positively regulate the cell cycle and MMP proteins (32, 33) . Thus, the role of LATS1 in cervical cancer invasion and proliferation may depend on its regulation on YAP, and its downstream target CTGF.
In conclusion, LATS1 is downregulated in human cervical cancers and LATS1 expression is associated with TNM stage. LATS1 inhibited cervical cancer cell proliferation and invasion, potentially through regulation of p27 and MMP9. LATS1 may activate the Hippo pathway through downregulation of YAP and CTGF. Loss of LATS1 may serve as an indicator of malignant phenotype in human cervical cancer.
